WallStSmart

Amphastar P (AMPH)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Takeda Pharmaceutical Co Ltd ADR generates 629200% more annual revenue ($4.69T vs $745.79M). AMPH leads profitability with a 13.3% profit margin vs 0.9%. TAK appears more attractively valued with a PEG of 0.48. AMPH earns a higher WallStSmart Score of 65/100 (C+).

AMPH

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 6.0Quality: 7.0
Piotroski: 3/9Altman Z: 2.23

TAK

Buy

56

out of 100

Grade: C

Growth: 4.7Profit: 5.5Value: 5.7Quality: 5.0
Piotroski: 4/9Altman Z: 1.20
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMPHUndervalued (+28.3%)

Margin of Safety

+28.3%

Fair Value

$39.87

Current Price

$29.37

$10.50 discount

UndervaluedFair: $39.87Overvalued

Intrinsic value data unavailable for TAK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMPH3 strengths · Avg: 8.7/10
EPS GrowthGrowth
135.1%10/10

Earnings expanding 135.1% YoY

P/E RatioValuation
13.1x8/10

Attractively priced relative to earnings

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

TAK5 strengths · Avg: 9.4/10
PEG RatioValuation
0.4810/10

Growing faster than its price suggests

Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Free Cash FlowQuality
$212.65B10/10

Generating 212.6B in free cash flow

Market CapQuality
$67.16B9/10

Large-cap with strong market position

Operating MarginProfitability
24.5%8/10

Strong operational efficiency at 24.5%

Areas to Watch

AMPH3 concerns · Avg: 2.7/10
Market CapQuality
$1.22B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.772/10

Expensive relative to growth rate

TAK4 concerns · Avg: 2.5/10
Return on EquityProfitability
5.2%3/10

ROE of 5.2% — below average capital efficiency

Profit MarginProfitability
0.9%3/10

0.9% margin — thin

P/E RatioValuation
300.3x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-9.8%2/10

Earnings declined 9.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMPH

The strongest argument for AMPH centers on EPS Growth, P/E Ratio, Price/Book.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.48 suggests the stock is reasonably priced for its growth.

Bear Case : AMPH

The primary concerns for AMPH are Market Cap, Piotroski F-Score, PEG Ratio.

Bear Case : TAK

The primary concerns for TAK are Return on Equity, Profit Margin, P/E Ratio. A P/E of 300.3x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

AMPH carries more volatility with a beta of 0.94 — expect wider price swings.

AMPH is growing revenue faster at 8.2% — sustainability is the question.

TAK generates stronger free cash flow (212.6B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AMPH scores higher overall (65/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amphastar P

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?